Stocks Health care CELU
NASDAQ · Health careCelularity Inc (CELU)
Celularity Inc brought in $19M of revenue over the twelve months to March 31, 2026, down 62.8% from a year earlier. It posted a net loss of $71.1M. At March 31, 2026 it held $368K in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on September 29, 2026.
Key facts about Celularity Inc
- Net worth
- Celularity Inc has a market value (market cap) of $20.6M at the latest share price, and shareholders' equity of -$35.3M on its balance sheet at March 31, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $26.6M (-51.0% year on year), with a net loss of $91.7M. Over the 12 months to March 31, 2026: revenue $19M, net loss $71.1M.
- Cash flow
- In fiscal 2025 operations used $13.3M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on September 29, 2026 and covers the period to March 31, 2026. Open on SEC EDGAR
- Next earnings report
- Celularity Inc's next report is expected around March 1, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Celularity Inc does
Celularity Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker CELU.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $26.6M | -$91.7M | -$3.59 | n/a |
| 2024 | $54.2M | -$57.9M | -$2.64 | -$6.6M |
| 2023 | $22.8M | -$196.3M | -$11.02 | -$39.7M |
| 2022 | $18M | $14.2M | $0.95 | -$143.1M |
| 2021 | $21.3M | -$100.1M | -$15.73 | -$116.3M |
| 2020 | $14.3M | -$208.2M | -$119.38 | -$91M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where CELU ranks in Health care
Latest SEC filings
What Celularity Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 29, 2026Executive or director change8-KCelularity appointed Viome founder Naveen Jain to its board of directors following the resignation of director Diane Parks.
- September 29, 2026Quarterly report10-Q · period to March 31, 2026Celularity reported a 66.3% drop in quarterly revenue and noted substantial doubt regarding its ability to continue as a going concern.Revenue fell 66% to $3.8M versus the same quarter last year; diluted EPS $0.02 versus -$0.84.
- September 28, 2026Activist stake changed SCHEDULE 13D/A
- September 28, 2026Executive or director change8-KCelularity secured up to $25.0 million in convertible note financing and settled outstanding debt disputes with Helena Global.
- September 14, 2026Other event 8-K
- August 14, 2026Late quarterly report notice NT 10-Q
- August 7, 2026
- July 29, 2026
- July 22, 2026Delisting notice 25-NSE
- June 30, 2026
Insider trades
What the people running Celularity Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| April 13, 2026 | Hariri Robert JChief Executive Officer, Director | Exercised options | 3,281 | - |
| April 13, 2026 | Hariri Robert JChief Executive Officer, Director | Shares withheld for tax | 1,182 | $1.5K |
| April 13, 2026 | Haines John RSenior Exec Vice President | Exercised options | 1,641 | - |
| April 13, 2026 | Haines John RSenior Exec Vice President | Shares withheld for tax | 583 | $746.2 |
| April 13, 2026 | Brigido StephenPres., Functional Regeneration | Exercised options | 821 | - |
| April 13, 2026 | Brigido StephenPres., Functional Regeneration | Shares withheld for tax | 268 | $343 |
| January 12, 2026 | LeVien VincentDirector | Received as pay | 28,847 | - |
| January 12, 2026 | Ling Geoffrey M.D.Director | Received as pay | 19,231 | - |
Who owns CELU
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Lim Kok Thay13D, may seek influence with 3 related filers | 41% | July 28, 2025 |
| Philip & Daniele Barach Family Trust13D, may seek influence with 2 related filers | 29% | September 28, 2026 |
Largest institutional holders
Insiders
7 insiders reported holding 4,217,250 shares in total, about $3.2M at the last price.
| Holder | Shares |
|---|---|
| Hariri Robert JChief Executive Officer, Director | 2,853,553 |
| Parks Diane L.Director | 520,021 |
| Diamandis PeterDirector | 394,150 |
| Ling Geoffrey M.D.Director | 256,026 |
| LeVien VincentDirector | 153,847 |
| Haines John RSenior Exec Vice President | 30,179 |
| Brigido StephenPres., Functional Regeneration | 9,474 |
Questions about CELU
What does Celularity Inc do?
Celularity Inc is a company in the Health care sector, listed on NASDAQ as CELU. Its shares trade on NASDAQ under the ticker CELU.
What is Celularity Inc's net worth?
Celularity Inc has a market value (market cap) of $20.6M at the latest share price, and shareholders' equity of -$35.3M on its balance sheet at March 31, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Celularity Inc profitable?
No. Over the twelve months to March 31, 2026 it reported a net loss of $71.1M on revenue of $19M.
How much revenue does Celularity Inc make?
Over the twelve months to March 31, 2026 Celularity Inc reported revenue of $19M. That is 62.8% less than a year earlier.
When did Celularity Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on September 29, 2026. It covers the period to March 31, 2026.
When is Celularity Inc's next earnings report?
Celularity Inc's next report is expected around March 1, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare CELU with
Follow CELU
Get an email when Celularity Inc files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Celularity Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.